Pharmacy Prior Authorization Criteria

Talvey (talquetamab-tgvs)

Indications for Prior Authorization

Talvey (talquetamab-tgvs)

• For diagnosis of Multiple Myeloma
  Indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

  This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Criteria

Talvey

Prior Authorization (Initial Authorization)

Length of Approval: 12 Month(s)

• Diagnosis of multiple myeloma
AND
• Disease is one of the following:
• Relapsed
• Refractory
AND
• Patient has received at least four prior lines of therapy which include all of the following:
• An immunomodulatory agent (e.g., lenalidomide, thalidomide)
• A proteasome inhibitor (e.g., bortezomib, carfilzomib)
• A CD38-directed monoclonal antibody (e.g., daratumumab)

Talvey

Prior Authorization (Reauthorization)

Length of Approval: 12 Month(s)

• Patient does not show evidence of progressive disease while on therapy

P & T Revisions

2024-10-02, 2023-09-28, 2023-09-28, 2023-09-28, 2022-12-05

References

1. Talvey Prescribing Information. Janssen Biotech, Inc. Horsham, PA. August 2023.

---

Revision History

• 2024-10-02: 2024 Annual Review - no changes
• 2023-09-28: New program
• 2023-09-28: New program
• 2023-09-28: New program
• 2022-12-05: New program for Tecvayli

---